US/UK/Canada

Share

Contacts

  • Rikard Akhtarzand

    CEO


    Tegeluddsvägen 76, SE 115 28 Stockholm, Sweden
    08 128 766 00
    http://www.addvisegroup.com
    • Pick a time period -

    ADDvise Group’s nomination committee for the annual general meeting 2020

    In accordance with the resolution at the 2019 annual general meeting of ADDvise Group AB the nomination committee for the annual general meeting 2020 shall be composed of representatives of the three largest shareholders by votes listed in the shareholders’ register maintained by Euroclear Sweden as of 31 August 2019 and the chairman of the board of directors acting as rapporteur. The representative appointed by the largest shareholder by votes shall be appointed chairman of the nomination committee. The nomination committee has now been appointed and comprises the following members:

    ADDvise Group’s reporting dates 2020

    Year-end report 2019 (Jan-Dec): 2020-02-20 Annual shareholder meeting: 2020-04-24 Three-month report (Jan-March): 2020-04-24 Six-month report (Jan-Jun): 2020-07-24 Nine-month report (Jan-Sep): 2020-10-23 Year-end report 2020 (Jan-Dec): 2021-02-25   For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se   About ADDvise GroupADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business

    ADDvise receives order worth approximately MSEK 3.3 - Regulatory information

    ADDvise Group AB's (publ) subsidiary Sonar Oy has received an order from Helsinki University Hospital worth approximately MSEK 3.3 regarding detectors for Samsung DR systems that will be used for image capturing. Delivery of the equipment is planned to take place at the end of 2019.  For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information: This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on November 21,

    ADDvise Group’s subsidiary receives order worth approximately 2.2 MSEK- regulatory information

    ADDvise Group AB’s (publ) subsidiary AB Germa has received an order from their distributor Bisco worth approximately 2.2 MSEK. The equipment will be used for immobilization of trauma patients and will be used by ambulance personnel in the Middle East. Delivery is planned to take place during Q4 2019 and Q1 2020.  For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information: This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted

    ADDvise Group AB (publ) conducts a directed issue of B shares of approximately MSEK 6.0 with the aim of paying earnouts related to completed acquisitions – Regulatory information

    The Board of Directors of ADDvise Group AB (publ) ("ADDvise" or the “Company"), supported by the authorization that the board of directors received at the Annual General Meeting on April 25, 2019, decided on a directed cash issue of 8,823,529 B-shares at a subscription price of 0.68 SEK per share to an institutional investor (the "Directed Issue"). Through the Directed Issue the Company receives approximately MSEK 6.0, before transaction costs. Summary · The subscription price amounts to SEK 0.68 per share, corresponding to a premium of one point forty-nine (1.49) percent compared

    ADDvise receives allocation decision worth approximately 3 MSEK - Regulatory information

    ADDvise Group AB's (publ) subsidiary Sonar Oy has received an allocation decision regarding the delivery of X-ray systems to Päijät-Häme Central Hospital in Lahti to a total value of approximately 3 MSEK. Delivery of the equipment is planned to take place during Q4 2019. The decision is subject to an appeal time expiring July 1st 2019. For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information: This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The

    ADDvise receives order worth approximately 8.7 MSEK - Regulatory information

    ADDvise Group AB's (publ) subsidiary Sonar Oy has received an order from Tampere University Hospital in Finland worth approximately 8.7 MSEK regarding X-ray equipment. The equipment will be used for medical diagnostics. Delivery of the equipment is planned to take place between Q3 2019 – Q1 2020.   For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se Important information: This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication

    ADDvise receives order worth approximately 2.8 MSEK - Regulatory information

    ADDvise Group AB's (publ) subsidiary Sonar Oy has received an order from Tampere University Hospital in Finland worth approximately 2.8 MSEK regarding image capturing equipment that will be used at the hospital’s X-ray department. Delivery of the equipment is planned to take place during Q3/Q4 2019.  For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se  Important information: This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for

    ADDvise order intake increased by 33% in Q1 2019 - Regulatory information

    ADDvise Group had a strong order intake during the first quarter of the year. Order intake increased by 33 percent compared with the previous year. The total order intake amounted to SEK 84.4 million. ADDvise Group's total order intake during the first quarter of 2019 amounted to SEK 84.4 million, compared with SEK 63.5 million in the first quarter of 2018. The total increase was 33 percent and organic growth was 20 percent compared to Q1 2018. -      The first quarter's order intake has started strongly. The trend has continued into the beginning of the second quarter. Our US

    ADDvise receives allocation decision worth approximately 2.7 MSEK - Regulatory information

    ADDvise Group AB's (publ) subsidiary Sonar Oy has received an allocation decision from Oulaskangas Hospital worth approximately 2.7 MSEK regarding X-ray equipment. Delivery of the equipment is planned to take place during Q3 2019.- We are glad that we through our latest acquisition are strengthening ADDvise’s position on the Finnish market. ADDvise is developing the future healthcare and we are very proud over that says Rikard Akhtarzand, CEO of ADDvise Group.The appeal time for the allocation decision expires April 17th 2019. For further information, please contact:Rikard

    ADDvise finalizes acquisition of Sonar Oy – Regulatory information

    ADDvise Group AB (publ) (”ADDvise”) has today finalized the acquisition of Sonar Oy (“Sonar”) that has previously been communicated through a press release published February 28th, 2019. The purchase price amounts to 3.2 MEUR, with two possible earn-outs. Sonar in brief Sonar Oy is a Finnish med-tech company. The product portfolio, among other products, consists of ultrasound and X-ray equipment. The revenue for 2018 amounted to approximately 7.0 MEUR with an adjusted EBITDA of approximately 0.8 MEUR.  Purchase price and financing The initial purchase price amounts to 3.2 MEUR

    ADDvise Group AB receives order for a value of 2,5 MSEK - Regulatory information

    ADDvise Group AB´s (publ) subsidiary LabRum has received an order from a world leading diagnostic company with it´s headquarters in Geneva, to a value of 2,5 MSEK. The order relates to laboratory furnishings for diagnostic sampling labs. Delivery is planned to Q2 2019. For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se  Important information:  This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on March 21, 2019 at 11:00 CET.

    ADDvise Group receives order worth 2,7 MSEK - Regulatory information

    ADDvise Group AB´s (publ) subsidiary LabRum has received an order from a biotechnology company focusing on tomorrow´s biopharmaceutical, to a value of 2,7 MSEK. The order relates to laboratory furniture for a newly built laboratory. Delivery is planned to Q2 2019. For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se  Important information:  This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on March 15, 2019 at 14:00 CET.

    ADDvise receives allocation decision worth approximately 14.4 MSEK – Regulatory information

    ADDvise Group AB’s (publ) subsidiary Hettich Labinstrument AB has received an allocation decision from Västra Götalandsregionen worth approximately 14.4 MSEK regarding blood sampling products. The period of the agreement is two years and starts in May 2019 with the possibility of an extension for a total of two years corresponding to an additional 14.4 MSEK. The time for appeal has expired.   For further information, please contact: Rikard Akhtarzand, CEO. +46 765-25 90 71 rikard.akhtarzand@addvisegroup.se www.addvisegroup.se Important information   This information

    Postponed date of closing of Sonar Oy – Regulatory information

    ADDvise Group AB (publ) (”ADDvise”) expect the date of closing of Sonar Oy (“Sonar”) to be April 1st 2019, instead of March 1st 2019 as previously stated in a press release from February 11th 2019. Advisor Mangold Fondkommission AB is the financial adviser and Krogerus is the legal advisor to ADDvise in connection with the Acquisition.  For further information, please contact: Rikard Akhtarzand, CEO. +46 765-25 90 71 rikard.akhtarzand@addvisegroup.se www.addvisegroup.se Important information   This information is required for ADDvise to disclose under the EU

    ADDvise Group AB (publ) proposes directed issue to guarantors in connection with the previously oversubscribed rights issue – Regulatory information

    ADDvise Group AB (publ) ("ADDvise" or the “Company") has completed the rights issue of 43,042,288 units that was announced on December 12, 2018 (the "Rights Issue"). In connection therewith, directed issues are carried out in accordance with the guarantee agreement with the guarantors of the Rights Issue who have chosen to receive guarantee remuneration in the form of shares (the "Remuneration Issues"). The subscription price in the Remuneration Issues is set at SEK 0.638 per share and payment is made through cancellation of claim. As communicated in connection with the Rights Issue, the

    ADDvise enters into an agreement to acquire Sonar Oy

    ADDvise Group AB (publ) (”ADDvise”) has today entered into an agreement with the shareholders of the Finnish company Sonar Oy (“Sonar”) regarding the acquisition of all shares in Sonar. The closing is expected to take place on March 1st, 2019 (the “Acquisition”). The signing of the Letter of Intent regarding the Acquisition was made public in a press release on December 12th, 2018. · The purchase price amounts to MEUR 3.2 (corresponding to MSEK 33.6) and is based on a cash and debt free basis and will be paid in cash. · An earn-out of a maximum of MEUR 1.1 (corresponding to MSEK 11.

    ADDvise Group AB (publ) - Rights Issue of approximately SEK 24.9 million is oversubscribed – Regulatory information

    ADDvise Group AB (publ) (”ADDvise” or the “Company”) has completed the rights issue of 43 042 288 units that was published December 12th2018 (the ”Rights Issue”). The Rights Issue has been subscribed to a total of 106.1 percent, which approximately 92.3 percent was subscribed for with preferential unit rights and approximately 13.8 percent were subscribed without preferential unit rights. Through the Rights Issue, the Company is allocated approximately SEK 24.9 million before issue costs. Allotment of units subscribed without preferential unit rights has been made in accordance with the

    ADDvise Group AB (publ) publishes updated preliminary Pro-forma financials for the ongoing acquisition- Regulatory notice

    Updated financials ADDvise has prepared updated preliminary financials to clarify the impact of ADDvise's latest acquisitions on ADDvise's financials, as well as the ongoing acquisition of the previously mentioned Finnish medtech company the (“Company”) expected effect on the financials. ADDvise preliminary full year 2018 (“Prel FY 18”) financials correspond to a net sales growth of 17.7 percent and an EBITDA growth of 18.7 percent compared to fiscal year of 2017. Proforma Prel FY 18 compared to ADDvise Prel FY 18 corresponds to a net sales growth of 25.2 percent and an EBITDA growth of

    ADDvise Groups revenue and EBT for Q4 2018 better than anticipated – Regulatory information

    ADDvise Group has made a preliminary assessment of the Group revenue and earnings before tax (EBT) for the fourth quarter 2018. Revenue and EBT show strong improvement when compared to the fourth quarter 2017. Revenue in Q4 2018 is estimated to reach 73 MSEK compared to 62 MSEK in Q4 2017, an increase by over 17 %. Earnings before tax (EBT) in Q4 2018 is estimated to reach 1,4 MSEK compared to -7,4 MSEK in Q4 2017. -        The EBT is driven by the positive revenue trend combined with the effect from synergies in acquired businesses, says Rikard Akhtarzand in a comment to the

    ADDvise enters into agreement with value of approximately 7,2 MSEK- Regulatory information

    ADDvise Group AB's (publ) subsidiary Surgical Tables Inc (STI) has entered into an agreement with one of the world's three largest medtech companies with a value of approximately 7,2 MSEK, meaning that STI will produce the newly developed surgical table for spinal fusion procedures. STI has received a first suborder within the framework of the agreement to a value of approximately 2,6 MSEK.Spinal fusion is a surgical technique that joins two or more vertebrae in order to reduce back pain. The newly developed surgical table shortens the operating time, reduces pain for the patient and

    ADDvise Group publishes an investment memorandum related to its guaranteed rights issue- Regulatory notice

    The Board of Directors in ADDvise Group AB (publ) ("the Company") publishes an investment memorandum related to the guaranteed rights issue of 24,9 MSEK of units (each consisting of one share of series B and one warrant) by the Company (Rights Issue). The Investment memorandum can now be found on the Company’s webpage www.addvisegroup.se/investor-relations/prospekt-2/ as well as Mangold’s webpage www.mangold.se/aktuella-emissioner-2/ -        The subscription period of the Rights Issue is between January 17th 2019 and January 31st 2019. -        Trading with unit rights takes place

    Analyst Group publishes research report of ADDvise Group

    Today ADDvise Group announces that Analyst Group published a research report of ADDvise Group on Analyst Group’s website and can be found at https://analystgroup.se/analysis/addvise-group/ For further information, please contact:Rikard Akhtarzand, CEO+46 765-25 90 71rikard.akhtarzand@addvisegroup.se About ADDvise GroupADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe